Deepak Sampath - Principal Scientist, Translational Oncology

Deepak Sampath

Principal Scientist, Translational Oncology

Years at Genentech

I joined Genentech in 2006 in the Oncology Department’s in vivo pharmacology group. Prior to Genentech, I was a Principle Scientist at Wyeth Research in the Department of Oncology focusing on the discovery and preclinical pharmacology of novel anti-microtubule agents. Since joining Genentech I have worked on small molecule drug discovery programs focusing on two areas of interest that include targeting the PI3K pathway and Bcl-2 family of pro-survival proteins. The best part of my job as a pharmacologist at Genentech is the opportunity to work with a number of highly motivated, passionate and extremely talented preclinical and clinical scientists all of whom share a common goal to discover and develop medicines that will help patients.

Featured Publication

Expression Profile of BCL-2, BCL-XL, and MCL-1 Predicts Pharmacological Response to the BCL-2 Selective Antagonist Venetoclax in Multiple Myeloma Models.

Mol Cancer Ther. 2016 May;15(5):1132-44.

Punnoose E, Leverson JD, Peale F, Boghaert ER, Belmont L, Tan N, Young A, Mitten M, Ingalla E, Darbonne W, Oleksijew A, Tapang P, Yue P, Oeh J, Lee L, Maiga S, Fairbrother WJ, Amiot M, Souers AJ, Sampath D.